Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Maravai Lifesciences Holdings (MRVI) EBIT (2020 - 2025)

Maravai Lifesciences Holdings has reported EBIT over the past 6 years, most recently at -$58.8 million for Q4 2025.

  • Quarterly results put EBIT at -$58.8 million for Q4 2025, down 55.95% from a year ago — trailing twelve months through Dec 2025 was -$215.3 million (up 8.64% YoY), and the annual figure for FY2025 was -$215.3 million, up 8.64%.
  • EBIT for Q4 2025 was -$58.8 million at Maravai Lifesciences Holdings, down from -$41.0 million in the prior quarter.
  • Over the last five years, EBIT for MRVI hit a ceiling of $180.7 million in Q2 2022 and a floor of -$165.6 million in Q3 2024.
  • Median EBIT over the past 5 years was -$9.4 million (2023), compared with a mean of $32.3 million.
  • Biggest five-year swings in EBIT: surged 1790.83% in 2021 and later crashed 974.23% in 2024.
  • Maravai Lifesciences Holdings' EBIT stood at $154.5 million in 2021, then decreased by 29.31% to $109.2 million in 2022, then crashed by 106.54% to -$7.2 million in 2023, then tumbled by 427.3% to -$37.7 million in 2024, then crashed by 55.95% to -$58.8 million in 2025.
  • The last three reported values for EBIT were -$58.8 million (Q4 2025), -$41.0 million (Q3 2025), and -$66.3 million (Q2 2025) per Business Quant data.